Processa Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage biopharmaceutical company focused on utilizing its proprietary Regulatory Science approach to develop Next Generation Chemotherapy (NGC) oncology drug products. The company's core strategy is to modify existing FDA-approved cancer therapies to alter their metabolism, distribution, and/or elimination, thereby improving their therapeutic index (safety and efficacy) while maintaining their established cancer-killing mechanisms. Its lead clinical pipeline includes NGC-Cap (PCS6422 combined with capecitabine) for advanced or metastatic breast cancer and other solid tumors, and PCS11T (NGC-Iri) for lung, pancreatic, and ovarian cancers.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing modified versions of FDA-approved oncology drugs (such as PCS6422/NGC-Cap and PCS-128) to improve safety, tolerability, and efficacy by altering their metabolism and distribution.
Expected impact: Aims to achieve faster clinical adoption and regulatory approval through a proprietary Regulatory Science Approach.
Actively pursuing strategic partnerships, licensing agreements, and establishing dedicated subsidiaries (such as for PCS499) to unlock value from non-oncology assets.
Expected impact: Provides non-dilutive funding and strategic flexibility while allowing the company to focus resources on core oncology programs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Monetizes the non-core asset PCS12852 for gastroparesis, allowing Processa to focus on oncology while retaining significant financial upside.
Terms: Processa received a $20,000 standstill payment and is eligible for a 3.5% equity stake in Intact, $2.5 million in licensing payments ($1.0 million within 30 days of closing and $1.5 million within 12 months), up to $454 million in development, regulatory, and commercial milestones, and a 12% royalty on worldwide net sales (excluding South Korea).